Showing 3301-3310 of 5646 results for "".
- Santen: VISIONARY Study Demonstrates Effectiveness of Tafluprost/Timolol Combination Therapy in Open-Angle Glaucomahttps://modernod.com/news/santen-visionary-study-demonstrates-effectiveness-and-tolerability-of-tafluprost-timolol-combination-therapy-in-open-angle-glaucoma/2477305/Santen has announced that the results of its real world evidence study, VISIONARY, have been published in Advances in Therapy. The study, which was conducted in 12 countries from across Europe with up to 6-mo
- Artificial Iris From HumanOptics Now Reimburseable Medical Producthttps://modernod.com/news/artificial-iris-from-humanoptics-now-reimburseable-medical-product/2477301/HumanOptics AG has received health insurance approval for its artificial iris Customflex ArtificialIris in the United States. Approval by the state Centers for Medicare and Medicaid Services (CMS) as a reimbursable me
- LumiThera to Expand Research into Diabetic Retinopathy for Valeda Light Delivery Systemhttps://modernod.com/news/lumithera-to-expand-research-into-diabetic-retinopathy-for-valeda-light-delivery-system/2477299/LumiThera announced it has initiated further studies with the University of Wisconsin-Milwaukee to establish the use of their Photobiomodulation platform in diabetic retinopathy (DR). “Recent research in our labs in both preclinical and clinical areas hav
- Santen and Verily Establish Joint Venture to Develop and Commercialize Unique Ophthalmic Deviceshttps://modernod.com/news/santen-and-verily-establish-joint-venture-to-develop-and-commercialize-unique-ophthalmic-devices/2477285/Santen Pharmaceutical and Alphabet subsidiary Verily announced the establishment of a joint venture focused on applying microelectronics and scalable digital technologies to ophthalmology. The new joint venture is driven by a mission to improve eye health for people everywhere, starting by
- Oculis Announces Positive OCS-01 Phase 2 Data in Patients with Diabetic Macular Edema (DME)https://modernod.com/news/oculis-announces-positive-ocs-01-phase-2-data-in-patients-with-diabetic-macular-edema-dme/2477287/Oculis reported positive data from a phase 2 study of OCS-01, a novel eye drop formulation of dexamethasone, in development for the treatment of diabetic macular edema (DME), according to a company news release. OCS-01 was developed using Oculis’ proprietary Soluble NanoParticle technolog
- Mojo Vision Developing Smart Contact Lenshttps://modernod.com/news/mojo-vision-developing-smart-contact-lens/2477237/Mojo Vision announced it is building what it calls the “world’s first true smart contact lens,” called the Mojo Lens. Mojo Lens is a contact lens with a built-in display that gives people useful and timely information without forcing them to look down at a screen or losing focus on th
- Analysis: FDA’s Efforts to Speed Drug Approval May Have Led to Less Rigorous Clinical Outcome Requirementshttps://modernod.com/news/analysis-fdas-efforts-to-speed-drug-approval-may-have-led-to-less-rigorous-clinical-outcome-requirements/2477231/An analysis published in JAMA suggests that efforts by the FDA to speed the development and approval of drugs may have led to a reduction in the amount of evidence available at the time of authorization by the agency and an increase in more surrogate measures. However, the authors noted
- Eyevensys Closes $30M Series B Financinghttps://modernod.com/news/eyevensys-closes-30m-series-b-financing/2477210/Eyevensys announced that it has completed a $30 million Series B financing. The company will use the funds to continue the development of its clinical lead candidate EYS606 for the treatment of chronic noninfectious uveitis (NIU), including the launch of its Electro Study. This phase 2 trial, to
- With EyeCare Partners Deal, Swiss Firm Sees a Base for ‘Organic Growth, Expansion and Consolidation’ of U.S. Vision Markethttps://modernod.com/news/with-eyecare-partners-deal-swiss-firm-sees-a-base-for-organic-growth-expansion-and-consolidation-of-u-s-vision-market/2477176/In the second major acquisition of an eyecare practice management group this year, the Switzerland-based Partners Group announced Monday morning that it has agreed to make a significant investment in EyeCare Partners LLC (ECP). FFL Partners announced separately that it was selling the stake it ha
- UK Regulator Unconditionally Clears Roche’s Purchase of Spark Therapeuticshttps://modernod.com/news/uk-regulator-unconditionally-clears-roches-purchase-of-spark-therapeutics/2477170/The UK Competition and Markets Authority (CMA) announced Monday the clearance of Roche’s proposed purchase of Spark Therapeutics after concluding that the deal would not negatively affect competition for haemophilia A treatments. The Swiss drugmaker noted that the offer period under the tra